KyungDong Pharm home
Prescription Medicines

Vidien inj.

Product Category
Vitamin D3 injection
Active Ingredients
Cholecalciferol
Appearance
Unscented, light yellow transparent injection solution contained in a brown transparent ampoule.
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 ampoule (1ml)
- Active ingredient: Cholecalciferol (EP)---------5mg
- Additives (animal-derived ingredients); Cholecalciferol (sheep, wool lead)
- Other additives: medium chain triglyceride

2. Effectiveness
1. Prevention and treatment of vitamin D deficiency in elderly and adolescents with vitamin D deficiency
2. Treatment of vitamin D deficiency in adults with vitamin D deficiency

3. Dosage and dosage
Use according to the doctor's prescription, but adjust the dosage by checking the amount of 25-hydroxy vitamin D in the blood.
After administering this drug, the treatment effect and tolerability should be reviewed within 3 months for adults and 6 months for adolescents, and based on this, a decision is made on whether to re-administer. Adverse reactions increase with overdose, so do not administer more than necessary.

- Adults: Inject 200,000 IU of cholecalciferol intramuscularly.
- Adolescents: Inject 200,000 IU of cholecalciferol intramuscularly.
- Elderly: Inject 100,000 IU of cholecalciferol intramuscularly.

The annual dose should not exceed 600,000 IU of cholecalciferol.

4. Precautions for use
1. Warning
1) To avoid overdose, consider the total content of vitamin D when administering treatments containing vitamin D and foods fortified with vitamin D at the same time.
2) Monitor calcium concentration and discontinue administration if serum calcium exceeds 10.5 mg/dL or urine calcium exceeds 4 mg/kg/day for adults.
3) If calcium intake is high, monitor blood and urine calcium levels regularly.
2. Do not administer to the following patients.
1) Patients with hypersensitivity to the components of this drug
2) Patients with hypercalcemia and hypercalciuria
3) Patients with calcium stones
4) Patients with a history of kidney calcium stones or at risk of stone formation
5) Patients with renal impairment
6) Immobile patient in hospital bed
7) Sarcoidosis patients
8) Patients with pseudohypoparathyroidism
9) Pregnant and lactating women

3. Adverse reactions
1) The following adverse reactions may occur when administering cholecalciferol.
Headache, asthenia, fatigue, muscle pain, loss of appetite, weight loss, poor growth, nausea, vomiting, constipation, diarrhea, polydipsia, polyuria, dehydration, high blood pressure, calcium stones, tissue calcification of kidneys and blood vessels, kidney failure, excessive bone calcification, arrhythmia, mental symptoms, impaired awareness, arthralgia, myasthenia gravis, drowsiness, azotemia, hypersensitivity reaction, dry mouth, confusion, gas distension, abdominal pain, metallic taste, dry mouth, Rash, itching
Additionally, hypercalciuria, hypercalcemia, hyperphosphatemia, and hyperphosphaturia may occur.

2) Clinical trials
Adverse drug reactions reported in a 6-month placebo-controlled clinical trial targeting 84 adults (ages 20-64) were mainly administration site side effects, and newly identified adverse drug reactions were as follows.
Injection site granuloma, injection site nodule, injection site reaction, injection site urticaria, injection site infection

4. General precautions
1) In a clinical trial, cholecalciferol was administered to patients with vitamin D deficiency and the level of 25-hydroxy vitamin D and parathyroid hormone in the blood was evaluated.
2) Since adverse reactions increase with overdose, the amount of 25-hydroxy vitamin D in the blood must be monitored when administering this drug to patients with vitamin D deficiency (normally, blood 25-hydroxy vitamin D concentration less than 10 ng/ml).
3) Check serum creatinine by measuring it every 3-6 months. In particular, the elderly and patients taking cardiac glycosides or diuretics concomitantly should monitor serum creatinine levels regularly. If there are symptoms of renal dysfunction, appropriately reduce the dose or discontinue administration according to the patient's condition.
4) In patients who have abnormalities in renal excretion of calcium and phosphate, monitor the calcium concentration in the blood and urine.
5) Patients receiving benzothiadiazine derivative treatment should regularly monitor blood and urine calcium levels.

5. Interaction
1) Anticonvulsants such as phenytoin, barbitrates, and glucocorticoids can affect the action of vitamin D.
2) Cholestyramine, colestipol, and orlistat reduce the absorption of vitamin D and, in the case of chronic alcoholism, may reduce vitamin D retention in the liver.
3) Thiazide diuretics may reduce renal calcium excretion, resulting in hypercalcemia. Therefore, during long-term treatment, calcium levels in the blood and urine should be monitored.
4) During administration of vitamin D, calcium concentration increases, which increases the toxicity of cardiac glycosides and may cause arrhythmia. In these patients, ECG should be measured and blood and urine calcium levels should be observed.
5) Antacids containing aluminum may reduce the absorption of vitamin D, thereby inhibiting the effectiveness of this drug, and preparations containing magnesium may cause hypermagnesemia.
6) In animal tests, when calciferol and warfarin were administered together, the action of warfarin increased. Use caution when administering this drug and warfarin together.

6. Administration to pregnant women
1) Teratogenicity studies in animals have not been conducted.
2) Do not administer excessive amounts of vitamin D during pregnancy. Hypercalcemia can cause physical and mental retardation, lamellar aortic stenosis, and retinopathy in children. Therefore, this drug is not used by pregnant or lactating women.

7. Administration to children
Safety and efficacy in children under 12 years of age have not been established.

8. Treatment in case of overdose
1) In case of overdose, stop taking vitamin D and reduce calcium intake. It also increases diuresis and increases water intake.

9. Precautions for application
1) This medicine should not be mixed with other medicines.
2) After opening the ampoule, use it promptly and discard the remainder.

5. How to save
Light-proof sealed container, stored at 1~25℃

6. Packaging unit
1mL × 5 ampoules

7. Period of use
36 months from date of manufacture